



## **Autolus Therapeutics to Participate in Upcoming Investor Conferences**

May 29, 2025 at 4:05 PM EDT

LONDON, May 29, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the Company will participate in upcoming investor conferences.

### **William Blair 45<sup>th</sup> Annual Growth Stock Conference**

Management to host investor meetings

Date: June 3, 2025

Location: Chicago, IL

### **Jefferies Global Healthcare Conference**

Fireside Chat Presentation

Date and time: June 5, 2025; 3:10pm EDT / 20:10pm BST

Location: New York, NY

Presenter: Chief Executive Officer Dr. Christian Itin

### **Goldman Sachs 46<sup>th</sup> Annual Global Healthcare Conference**

Fireside Chat Presentation

Date and time: June 11, 2025; 1:20pm EDT / 18:20 BST

Location: Miami, FL

Presenter: Chief Financial Officer Rob Dolski

A webcast of the fireside chats will be available on the "Events" page in the "Investor Relations & Media" section of the Company's website at <https://www.autolus.com/investor-relations-media/events/>. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

### **About Autolus Therapeutics plc**

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies and candidates for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted and controlled T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved and MHRA licensed product, obe-cel, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit [www.autolus.com](http://www.autolus.com).

### **Contact:**

Amanda Cray

+1 617-967-0207

[a.cray@autolus.com](mailto:a.cray@autolus.com)

Olivia Manser

+44 7780 471 568

[o.manser@autolus.com](mailto:o.manser@autolus.com)